Analysts Maintain Prothena Price Target as Valuation Adjustments Reflect Recent Clinical Results

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

26 Mar 25

Updated

20 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-28.8%

7D

-0.8%

Loading

1Y

-28.8%

7D

-0.8%

You can edit this narrative until Nov 21 5:05 AM. Then, changes will post as Updates.

Author's Valuation

US$18.3343.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 20 Nov 25

Fair value Increased 11%

PRTA: Upcoming Partnered Pipeline Milestones Will Drive Substantial Upside Over Next Year

Analysts have increased their price target for Prothena, raising it from $16.50 to $18.33. They cite optimism about the company's partnered pipeline and upcoming catalysts as key drivers for this upward revision.

Shared on 05 Nov 25

Fair value Increased 27%

PRTA: Upcoming Pipeline Milestones Will Drive Bullish Momentum Over Next 12 Months

Analysts have increased their price target for Prothena significantly, raising it from $15 to $36. They cite the company's strong partnered pipeline as well as substantial potential from upcoming catalysts and milestone payments.

Shared on 22 Oct 25

Analysts have marginally raised their price target for Prothena from $13.00 to $13.00. They cited slight adjustments in discount rate and profit margin assumptions as drivers for the updated valuation.

Shared on 08 Oct 25

Fair value Increased 8.33%

Analysts have raised Prothena's fair value estimate by $1.00 to $13.00, citing improved profit margin forecasts and a slightly lower projected future price-to-earnings ratio. What's in the News Prothena announced results from the Phase 1 ASCENT clinical program for PRX012 in early symptomatic Alzheimer's disease.

Shared on 13 Sep 25

Fair value Decreased 20%

Prothena’s consensus price target has been revised down to $12.00, reflecting weaker expectations primarily due to a notable decline in net profit margin and a reduced future P/E multiple. What's in the News Prothena reported Phase 1 ASCENT program results for PRX012 in early symptomatic Alzheimer's, showing stable pharmacokinetics, low immunogenicity, significant amyloid reduction, but higher ARIA-E rates compared to FDA-approved antibodies; company plans to seek partnerships for PRX012 and PRX012-TfR.

Shared on 29 Aug 25

Fair value Decreased 38%

Despite a sharp upward revision in both revenue growth and net profit margin forecasts for Prothena, the consensus analyst price target has significantly decreased from $24.29 to $15.00. What's in the News Phase 1 ASCENT results for PRX012 in early symptomatic Alzheimer's showed promising amyloid plaque reduction and pharmacokinetics, but higher ARIA-E rates than approved therapies; Prothena will seek partnership to advance PRX012 and its preclinical Ab-TfR antibody.

Shared on 01 May 25

Fair value Decreased 53%

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 81.7x to 91.2x.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 113%

AnalystConsensusTarget has decreased revenue growth from 23.1% to 16.4%, increased profit margin from 10.5% to 19.3%, increased future PE multiple from 58.3x to 81.4x and increased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$18.33

43.5% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

31.89%

Biotech revenue growth rate

8.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.43%

Calculation

US$10.67m

Earnings '28

x

112.74x

PE Ratio '28

=

US$1.20b

Market Cap '28

US$1.20b

Market Cap '28

/

53.84m

No. shares '28

=

US$22.35

Share Price '28

US$22.35 Share Price '28

Discounted to 2025 @ 7.39% p.a.

=

US$18.05

Fair Value '25